152 related articles for article (PubMed ID: 38142245)
21. Epidemiology of Saccharomyces fungemia: A systematic review.
Vinayagamoorthy K; Pentapati KC; Prakash H
Med Mycol; 2023 Feb; 61(2):. PubMed ID: 36806741
[TBL] [Abstract][Full Text] [Related]
22. Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.
Li R; Wan X; Takala TM; Saris PEJ
Probiotics Antimicrob Proteins; 2021 Feb; 13(1):229-237. PubMed ID: 32567021
[TBL] [Abstract][Full Text] [Related]
23. New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.
Samakkarn W; Vandecruys P; Moreno MRF; Thevelein J; Ratanakhanokchai K; Soontorngun N
Appl Microbiol Biotechnol; 2024 Jan; 108(1):153. PubMed ID: 38240846
[TBL] [Abstract][Full Text] [Related]
24. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
[TBL] [Abstract][Full Text] [Related]
25. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
Wombwell E; Bransteitter B; Gillen LR
Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
[TBL] [Abstract][Full Text] [Related]
26. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
27. Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum.
Schroeder B; Winckler C; Failing K; Breves G
Dig Dis Sci; 2004 Aug; 49(7-8):1311-7. PubMed ID: 15387362
[TBL] [Abstract][Full Text] [Related]
28. Alcoholic and non-alcoholic rosé wines made with Saccharomyces cerevisiae var. boulardii probiotic yeast.
Mulero-Cerezo J; Tuñón-Molina A; Cano-Vicent A; Pérez-Colomer L; Martí M; Serrano-Aroca Á
Arch Microbiol; 2023 Apr; 205(5):201. PubMed ID: 37081186
[TBL] [Abstract][Full Text] [Related]
29. Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats.
Sun K; Ding M; Fu C; Li P; Li T; Fang L; Xu J; Zhao Y
J Ethnopharmacol; 2023 Apr; 306():116154. PubMed ID: 36634725
[TBL] [Abstract][Full Text] [Related]
30. Saccharomyces boulardii promoters for control of gene expression in vivo.
Sands C; Hedin KA; Vazquez-Uribe R; Sommer MOA
Microb Cell Fact; 2024 Jan; 23(1):16. PubMed ID: 38185666
[TBL] [Abstract][Full Text] [Related]
31. Effect of probiotic Saccharomyces boulardii in experimental giardiasis.
Ribeiro MRS; Oliveira DR; Oliveira FMS; Caliari MV; Martins FS; Nicoli JR; Torres MF; Andrade MER; Cardoso VN; Gomes MA
Benef Microbes; 2018 Sep; 9(5):789-797. PubMed ID: 30165752
[TBL] [Abstract][Full Text] [Related]
32. Effect of microencapsulation on
Ghorbani-Choboghlo H; Nikaein D; Khosravi AR; Rahmani R; Farahnejad Z
Iran J Microbiol; 2019 Apr; 11(2):160-165. PubMed ID: 31341571
[TBL] [Abstract][Full Text] [Related]
33. Anticancer Properties of Saccharomyces boulardii Metabolite Against Colon Cancer Cells.
Pakbin B; Allahyari S; Dibazar SP; Peymani A; Haghverdi MK; Taherkhani K; Javadi M; Mahmoudi R
Probiotics Antimicrob Proteins; 2024 Feb; 16(1):224-232. PubMed ID: 36547769
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial.
Salazar-Parra MA; Cruz-Neri RU; Trujillo-Trujillo XA; Dominguez-Mora JJ; Cruz-Neri HI; Guzmán-Díaz JM; Guzmán-Ruvalcaba MJ; Vega-Gastelum JO; Ascencio-Díaz KV; Zarate-Casas MF; González-Ponce FY; Barbosa-Camacho FJ; Fuentes-Orozco C; Cervantes-Guevara G; Cervantes-Pérez E; Cervantes-Cardona GA; Cortés-Flores AO; González-Ojeda A
BMC Gastroenterol; 2023 Jul; 23(1):229. PubMed ID: 37400812
[TBL] [Abstract][Full Text] [Related]
35. Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.
Kim J; Cheong YE; Yu S; Jin YS; Kim KH
Microb Cell Fact; 2022 Oct; 21(1):204. PubMed ID: 36207743
[TBL] [Abstract][Full Text] [Related]
36. Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide.
Liu CH; Chang JH; Chang YC; Mou KY
J Mol Med (Berl); 2020 Dec; 98(12):1675-1687. PubMed ID: 33025105
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
Cui B; Lin L; Wang B; Liu W; Sun C
Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
[TBL] [Abstract][Full Text] [Related]
38. Antihyperglycemic effects of three extracts from Momordica charantia.
Virdi J; Sivakami S; Shahani S; Suthar AC; Banavalikar MM; Biyani MK
J Ethnopharmacol; 2003 Sep; 88(1):107-11. PubMed ID: 12902059
[TBL] [Abstract][Full Text] [Related]
39. Development of a Novel ATP Bioluminescence Assay Based on Engineered Probiotic
Park JS; Kim YW; Kim H; Kim SK; Park K
J Microbiol Biotechnol; 2023 Nov; 33(11):1506-1512. PubMed ID: 37482802
[TBL] [Abstract][Full Text] [Related]
40. Anticancer Properties of Probiotic Saccharomyces boulardii Supernatant on Human Breast Cancer Cells.
Pakbin B; Dibazar SP; Allahyari S; Javadi M; Amani Z; Farasat A; Darzi S
Probiotics Antimicrob Proteins; 2022 Dec; 14(6):1130-1138. PubMed ID: 35094296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
